L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

ULSCs is under clinical development by RESTEM and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs for Dermatomyositis have a 91% phase transition success rate (PTSR) ...

The inflammatory myopaties such as polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory muscle disorders characterised by the development of proximal and often symmetrical muscle ...

Inflammatory Myositis Overview Myositis refers to muscle inflammation and is commonly associated with inflammatory myopathies, including polymyositis, dermatomyositis, cancer-associated myositis ...

It also discusses the signs and symptoms, diagnosis, and treatment of juvenile myositis. The most common form of JM is juvenile dermatomyositis (JDM). Juvenile polymyositis (JPM) can also occur in ...

Autoimmune myositis (AIM) is a group of diseases affecting skin and muscles in both children and adults. The spectrum of AIM includes polymyositis (PM), dermatomyositis (DM), immune-mediated ...

manchester.ac.uk Objectives: There is a known association between myositis and cancer. The risk is greater in dermatomyositis (DM) than polymyositis (PM), although reliable methods to predict cancer ...

Objective To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and ...